The FDA clearance follows Syneron’s receipt in Europe of CE mark clearance for the Matrix RF. Matrix RF utilizes Syneron’s radio frequency technology to provide effective ablation and resurfacing through fractional tissue heating at three ablation and resurfacing relative ratios.
The tunable Matrix RF applicator is equipped with the SelectPulse to enable customization of the depth of ablation and degree of skin resurfacing based on individual patient needs, the company said.
The Matrix RF applicator is said to be the first bi-polar RF non-laser and non-light-based aesthetic device capable of creating tunable ablation impact, simulating the effects of common ablative or coagulative lasers used for a range of aesthetic applications.
Doron Gerstel, CEO of Syneron, said: “As the first to introduce a bi-polar RF tunable fractional device for ablation and resurfacing, our physician partners benefit from both our investments in research and product development and our commitment to innovative treatments that will increase practice revenue.”